Close
Matthew Butler, MD
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Matthew Butler, MD
Matthew Butler, MD, is an assistant professor in the Division of Hematology and Oncology at The University of Texas Health Science Center at San Antonio. He's a hematologist-oncologist specializing in all areas of benign and malignant hematology, with a focus on multiple myeloma at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center.
Dr. Butler grew up in Nova Scotia, Canada, and graduated from the University of Toronto. He completed a Master of Science degree in Informatics at the University of Edinburgh, and worked for several years as a software developer before deciding to attend medical school.
He completed his residency in Internal Medicine at Geisinger Medical Center in Pennsylvania, followed by a fellowship in Hematology and Oncology at UT Health San Antonio. He conducts clinical treatment trials in myeloma and research into the metabolic factors that drive the disease's progression.
Gender
- Male
Languages Spoken
- English
-
Credentials
Credentials
Positions
- Assistant Professor, Division of Hematology and Oncology, University of Texas Health Science Center at San Antonio
Certifications
- American Board of Internal Medicine, Hematology
- American Board of Internal Medicine, Medical Oncology
- American Board of Internal Medicine, Internal Medicine
Education
- Medical School: Saba University School of Medicine, Caribbean Netherlands
- Residency: Internal Medicine, Geisinger Medical Center, Danville, PA
- Fellowship: Hematology and Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX
- Graduate: University of Edinburgh, Edinburgh, UK
- Undergraduate: University of Toronto, Toronto, ON
-
Locations & Contact
Locations & Contact
Dr. Butler is very informative. He's easy to speak to. He's very caring and I really liked his bed side manner.
Patient
-
Research & Publications
Research & Publications
Molecular characterization of a transformation from primary myelofibrosis into polycythemia vera: a case report
Matthew J Butler, Paul I Roda, Patrick Dorion
Isolated hemolytic anemia: an unusual manifestation of occult malignancy
Matthew J Butler, Ming Yin, Fahd Quddus
Biology Informs Treatment Choices in Diffuse Large B Cell Lymphoma
Matthew J Butler, Ricardo C T Aguiar
-
Clinical Trials
Clinical Trials
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Matthew Butler, MD
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib, and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM
To compare the progression-free survival (PFS) of mezigdomide (CC-92480, also known as BMS-986348), bortezomib and dexamethasone (MeziVd) to that of pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)
Type of Cancer
Myeloma
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Matthew Butler, MD
S2209, A Phase III Randomized Trial For Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail Or In A Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance
To compare progression-free survival (PFS) in frail or selected intermediate fit Newly Diagnosed Multiple Myeloma (NDMM) participants treated with VRd-Lite induction followed by Lenalidomide maintenance (Arm 1) versus DRd induction followed by Lenalidomide maintenance (Arm 2).To compare overall survival (OS) in frail or selected intermediate fit NDMM participants treated with VRd-Lite induction…